

Stricken language would be deleted from and underlined language would be added to the law as it existed prior to this session of the General Assembly.

1 State of Arkansas
2 85th General Assembly
3 Regular Session, 2005

A Bill

HOUSE BILL 2446

4
5 By: Representative Mahony
6
7

For An Act To Be Entitled

8
9 THE WHOLESALE LICENSURE AND PRESCRIPTION
10 MEDICATION INTEGRITY ACT.
11

Subtitle

12
13 THE WHOLESALE LICENSURE AND PRESCRIPTION
14 MEDICATION INTEGRITY ACT.
15
16

17 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:
18

19 SECTION 1. Arkansas Code Title 17, Chapter 92 is amended to add an
20 additional subchapter to read as follows:

21 17-92-1201. Definitions.

22 As used in this subchapter:

23 (1) "Authentication" means to affirmatively verify before any
24 prescription drug is distributed that each transaction listed on the pedigree
25 has occurred;

26 (2)(A) "Chain pharmacy warehouse" means a physical location for
27 drugs or devices, or both, that acts as a central warehouse and performs
28 intracompany sales or transfers of the drugs or devices, or both, to a group
29 of chain pharmacies that have common ownership and control.

30 (B) Chain pharmacy warehouses shall be licensed by the
31 Arkansas State Board of Pharmacy as chain pharmacy warehouses;

32 (3) "Facility" means the place of business of a wholesale
33 distributor at which prescription drugs are stored, handled, repackaged, or
34 offered for sale;

35 (4) "Intracompany sales" means any transaction or transfer
36 between any division, subsidiary, parent, or affiliated or related company



1 under common ownership and control of a corporate entity;

2 (5) "Normal distribution channel" means a chain of custody for a
3 medication that is transferred from a manufacturer to a wholesale
4 distributor, from a wholesale distributor to a pharmacy, and from a pharmacy
5 to a patient;

6 (6) "Pedigree" means a document or electronic file containing
7 information that records each distribution of any given prescription drug
8 from sale by a pharmaceutical manufacturer through acquisition and sale by
9 any wholesale distributor or repackager, until final sale to a pharmacy or
10 other person dispensing or administering the prescription drug;

11 (7) "Prescription drug" means any drug, including any
12 biological product, except for blood and blood components intended for
13 transfusion or biological products that are also medical devices, required by
14 federal law or regulation, or both, to be dispensed only by a prescription,
15 including finished dosage forms and bulk drug substances subject to § 503(b)
16 of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 301 et seq. as it
17 existed on January 1, 2005;

18 (8)(A) "Repackage" means repackaging or otherwise changing the
19 container, wrapper, or labeling of a prescription drug to further the
20 distribution of the drug.

21 (B) "Repackage" does not include repackaging or otherwise
22 changing the container, wrapper, or labeling of a prescription drug completed
23 by the pharmacist responsible for dispensing the drug to the patient;

24 (9) "Repackager" means a person who repackages; and

25 (10)(A) "Wholesale distributor" means anyone engaged in the
26 wholesale distribution of prescription drugs, including, but not limited to:

27 (i) Manufacturers, unless exempted by law;

28 (ii) Repackagers;

29 (iii) Own-label distributors;

30 (iv) Private-label distributors;

31 (v) Jobbers;

32 (vi) Brokers;

33 (vii) Warehouses, including, but not limited to:

34 (a) Manufacturers' warehouses; and

35 (b) Distributors' warehouses;

36 (viii) Drug wholesalers or distributors;

- 1 (ix) Independent wholesale drug traders;
- 2 (x) Retail pharmacies that conduct wholesale
- 3 distribution; and
- 4 (xi) Chain pharmacy warehouses that conduct
- 5 wholesale distribution.

6 (B) "Wholesale distributor" does not include:

- 7 (i) Intracompany sales of prescription drugs;
- 8 (ii) A sale, purchase, distribution, trade, or
- 9 transfer of a prescription drug or offer to sell, purchase, distribute,
- 10 trade, or transfer a prescription drug for emergency medical reasons;
- 11 (iii) A distribution of prescription drug samples by
- 12 a manufacturer's representative;
- 13 (iv) Drug returns, if the returns are conducted by a
- 14 hospital, health care entity, retail pharmacy, or charitable institution in
- 15 accordance with 21 C.F.R. § 203.23 as it existed on January 1, 2005;
- 16 (v) A sale of minimal quantities of prescription
- 17 drugs by retail pharmacies to licensed practitioners for office use; or
- 18 (vi) Delivery by a retail pharmacy of prescription
- 19 drugs to a patient or patient's agent under the order of a person licensed to
- 20 prescribe prescription drugs.

21
22 17-92-1202. Wholesale drug distributor licensing -- Minimum

23 requirements for licensure.

24 (a)(1) A wholesale distributor that engages in the wholesale

25 distribution of prescription drugs shall be licensed by the state licensing

26 authority in the state in which it resides.

27 (2) If a wholesale distributor that is not a resident of the

28 State of Arkansas ships prescription drugs into Arkansas in accordance with

29 this subchapter, the wholesale distributor shall be licensed by the Arkansas

30 State Board of Pharmacy before engaging in wholesale distribution of needed

31 prescription drugs in Arkansas.

32 (b) The board shall promulgate rules to require at least the following

33 information from each wholesale distributor applying for a license under

34 subsection (a) of this section, including, but not limited to:

35 (1) The name, full business address, and telephone number of the

36 applicant;

1 (2) All trade or business names used by the applicant;

2 (3) The addresses, telephone numbers, and names of contact
3 persons for all facilities used by the applicant for the storage, handling,
4 and distribution of prescription drugs;

5 (4) The type of ownership or operation, whether a partnership,
6 corporation, sole proprietorship, or other business entity;

7 (5) The name of the owner or operator, or both, of the
8 applicant, including:

9 (A) If a person, the name of the person;

10 (B) If a partnership, the name of each partner and of the
11 partnership;

12 (C) If a corporation, the name and title of each corporate
13 officer and director, the corporate names, and the name of the state of
14 incorporation; and

15 (D) If a sole proprietorship, the full name of the sole
16 proprietor and the name of the business entity;

17 (6) A list of all licenses and permits issued to the applicant
18 by any other state that authorizes the applicant to purchase or possess
19 prescription drugs;

20 (7) For the applicant's designated representative for the
21 facility, the designated representative's:

22 (A) Name;

23 (B) Fingerprints;

24 (C) Places of residence for the past seven (7) years;

25 (D) Date and place of birth;

26 (E)(i) Occupations, positions of employment, and offices
27 held during the past seven (7) years.

28 (ii) The information required under subdivision
29 (b)(7)(E)(i) of this section shall be accompanied by the name and address of
30 any business, corporation, or other organization for which the designated
31 representative worked during the past seven (7) years;

32 (F) Background information regarding any proceeding
33 against the designated representative for the revocation of any license, the
34 nature of the proceeding, and the disposition of the proceeding;

35 (G) For the past seven (7) years, background information
36 regarding whether the designated representative has been enjoined, either

1 temporarily or permanently, by a court of competent jurisdiction from
 2 violating any federal or state law regulating the possession, control, or
 3 distribution of prescription drugs, together with details concerning any such
 4 event;

5 (H)(i) For the past seven (7) years, a description of any
 6 involvement by the designated representative with any business, including any
 7 investments, other than the ownership of stock in a publicly traded company
 8 or mutual fund that manufactured, administered, prescribed, distributed, or
 9 stored pharmaceutical products.

10 (ii) The description shall include any lawsuits in
 11 which any of the businesses were named as a party;

12 (I)(i) Description of any felony criminal offense
 13 committed by the designated representative as an adult for which the
 14 designated representative was convicted, regardless of whether adjudication
 15 of guilt was withheld or whether the person pleaded guilty or nolo
 16 contendere.

17 (ii) If the designated representative indicates that
 18 a criminal conviction is under appeal and submits a copy of the notice of
 19 appeal of that criminal offense, the applicant shall submit to the board
 20 within fifteen (15) days after the disposition of the appeal a copy of the
 21 final written order of disposition; and

22 (J) A photograph taken within the previous thirty (30)
 23 days.

24 (c) The information required under subsection (b) of this section
 25 shall be provided under oath.

26 (d) The board shall not issue a wholesale distributor license to an
 27 applicant unless the board determines that the designated representative
 28 meets the following qualifications:

29 (1) Is at least twenty-one (21) years of age;

30 (2) Has been employed full time for at least three (3) years in
 31 a pharmacy or with a wholesale distributor in a capacity related to the
 32 dispensing and distribution of and recordkeeping relating to prescription
 33 drugs;

34 (3) Has received a score of seventy-five percent (75%) or higher
 35 on an examination given by the Arkansas State Board of Pharmacy
 36 regarding federal and state laws governing wholesale distribution of

1 prescription drugs;

2 (4) Is employed by the applicant full time in a managerial level
 3 position;

4 (5) Is actively involved in and aware of the actual daily
 5 operation of the applicant;

6 (6) Is physically present at the facility of the applicant
 7 during regular business hours, except when the absence of the designated
 8 representative is authorized, including, but not limited to, sick leave and
 9 vacation leave;

10 (7) Is serving in the capacity of a designated representative
 11 for only one (1) applicant at a time;

12 (8) Does not have any convictions under any federal, state, or
 13 local laws relating to wholesale or retail prescription drug distribution or
 14 the distribution of controlled substances; and

15 (9) Does not have any felony convictions under federal, state,
 16 or local laws.

17 (e) The board shall submit the fingerprints provided by a person with
 18 a license application for a statewide criminal record check and for
 19 forwarding to the Federal Bureau of Investigation for a national criminal
 20 record check of the person.

21 (f) The board shall require every wholesale distributor applying for a
 22 license to submit a bond of at least one hundred thousand dollars (\$100,000)
 23 or another equivalent means of security acceptable to the board, including,
 24 but not limited to:

25 (1) An irrevocable letter of credit; or

26 (2)(A) A deposit in a trust account or financial institution,
 27 payable to a fund established by the board under subsection (g) of this
 28 section.

29 (B)(i) The purpose of the bond is to secure payment of any
 30 finances or penalties imposed by the board and any fees and costs incurred by
 31 the board regarding the licensee that are authorized under state law and that
 32 the licensee fails to pay thirty (30) days after the fines, penalties, or
 33 costs become final.

34 (ii) The board may make a claim against the bond or
 35 security until one (1) year after the licensee's license ceases to be valid.

36 (iii) The bond shall cover all facilities operated

1 by the applicant in the state.

2 (g) The board shall establish a fund, separate from its other
3 accounts, in which to deposit the wholesale distributor bonds.

4 (h) If a wholesale distributor distributes prescription drugs from
5 more than one (1) facility, the wholesale distributor shall obtain a license
6 for each facility.

7 (i)(1) Each calendar year, the board shall send to each wholesale
8 distributor licensed under this section a form setting forth the information
9 that the wholesale distributor provided under subsection (b) of this section.

10 (2) Within thirty (30) days of receiving the form, the wholesale
11 distributor shall identify and state under oath to the board all changes or
12 corrections to the information that was provided under subsection (b) of this
13 section.

14 (3) Changes in or corrections to any information in subsection
15 (b) of this section shall be submitted to the board.

16 (4) The board may suspend or revoke the license of a wholesale
17 distributor if the board determines that the wholesale distributor no longer
18 qualifies for the license issued under this section.

19 (j) The designated representative identified under subdivision (b)(7)
20 of this section shall complete continuing education programs as required by
21 the board regarding federal and state laws governing wholesale distribution
22 of prescription drugs.

23 (k) Information provided under this section may not be disclosed to
24 any person or entity other than a state licensing authority, government
25 board, or government agency if the licensing authority, government board, or
26 government agency needs the information for licensing or monitoring purposes.

27
28 17-92-1203. Restrictions on transactions.

29 (a)(1)(A) Returns of prescription drugs and exchanges from a pharmacy
30 or chain pharmacy warehouse received by a wholesale distributor under the
31 terms and conditions of an agreement between the wholesale distributor and
32 the pharmacy or chain pharmacy warehouse shall not be subject to the pedigree
33 requirement of § 17-92-1204.

34 (B) A wholesale distributor shall be held accountable for
35 policing its returns process and ensuring that its operations are secure and
36 do not permit the entry of adulterated and counterfeit products.

1 (2) A wholesale distributor who meets the exception in this
 2 subsection (a) shall not receive from a pharmacy or chain pharmacy warehouse
 3 an amount or quantity of a prescription drug larger than the amount or
 4 quantity that was originally sold by the wholesale distributor to the
 5 pharmacy or chain pharmacy warehouse.

6 (b)(1) A manufacturer or wholesale distributor shall furnish
 7 prescription drugs only to a person licensed by the appropriate state
 8 licensing authority.

9 (2) Before furnishing prescription drugs to a person not known
 10 to the manufacturer or wholesale distributor, the manufacturer or wholesale
 11 distributor shall affirmatively verify that the person is authorized to
 12 receive the prescription drugs by contacting the appropriate state licensing
 13 authorities.

14 (c)(1) Prescription drugs furnished by a manufacturer or wholesale
 15 distributor shall be delivered only to the premises listed on the license.

16 (2) However, the manufacturer or wholesale distributor may
 17 furnish prescription drugs to an authorized person or agent of that person at
 18 the premises of the manufacturer or wholesale distributor if:

19 (A) The identity and authorization of the recipient is
 20 properly established; and

21 (B) This method of receipt is employed only to meet the
 22 immediate needs of a particular patient of the authorized person.

23 (d)(1) Prescription drugs may be furnished to a hospital pharmacy
 24 receiving area if a pharmacist or authorized receiving person signs at the
 25 time of delivery a receipt showing the type and quantity of the prescription
 26 drug received.

27 (2) Any discrepancy between a receipt and the type and quantity
 28 of the prescription drug actually received shall be reported to the
 29 delivering manufacturer or wholesale distributor by the next business day
 30 after the delivery to the pharmacy receiving area.

31 (e)(1) A manufacturer or wholesale distributor shall not accept
 32 payment for or allow the use of a person or entity's credit to establish an
 33 account for the purchase of prescription drugs from any person other than the
 34 owner of record, the chief executive officer, or the chief financial officer
 35 listed on the license of a person or entity legally authorized to receive
 36 prescription drugs.

1 (2) Any account established for the purchase of prescription
2 drugs shall bear the name of the licensee.

3
4 17-92-1204. Pedigree.

5 (a)(1) Each person who is engaged in wholesale distribution of
6 prescription drugs shall establish and maintain inventories and records of
7 all transactions regarding the receipt and distribution or other disposition
8 of the prescription drugs.

9 (2) The records shall include, but not be limited to:

10 (A) Pedigrees for all prescription drugs that leave the
11 normal distribution channel; and

12 (B) Pedigrees for all prescription drugs that are included
13 on the Specified List of Susceptible Products of the National Association of
14 Boards of Pharmacy as the list existed on January 1, 2005.

15 (3) Effective December 31, 2007, all wholesale distributors
16 whether located in or out of this state shall provide to the Arkansas State
17 Board of Pharmacy and maintain an electronic pedigree developed in accordance
18 with standards and requirements of the board for all prescription drugs
19 received and distributed.

20 (b) A retail pharmacy or chain pharmacy warehouse shall comply with
21 the requirements of this section only if the pharmacy or chain pharmacy
22 warehouse engages in wholesale distribution of prescription drugs.

23 (c) Each person who is engaged in the wholesale distribution of a
24 prescription drug, including repackagers, but excluding the original
25 manufacturer of the finished form of the prescription drug, who is in
26 possession of a pedigree for a prescription drug and attempts to further
27 distribute that prescription drug shall affirmatively verify before any
28 prescription drug is distributed that each transaction listed on the pedigree
29 has occurred.

30 (d) The pedigree shall include all necessary identifying information
31 concerning each sale in the chain of distribution of the product from the
32 manufacturer through acquisition and sale by any wholesale distributor or
33 repackager until final sale to a pharmacy or other person dispensing or
34 administering the drug.

35 (e) The necessary chain of distribution information shall include, but
36 not be limited to:

1 (1) The name, address, telephone number, and if available, the
 2 e-mail address of each owner of the prescription drug and each wholesale
 3 distributor who does not take title to the prescription drug;

4 (2) The name and address of each location from which the product
 5 was shipped, if different from the owner's;

6 (3) Transaction dates; and

7 (4) Certification that each recipient has authenticated the
 8 pedigree.

9 (f) The pedigree shall also include, but not be limited to:

10 (1) The name of the prescription drug;

11 (2) The dosage form and strength of the prescription drug;

12 (3) The size of the container;

13 (4) The number of containers;

14 (5) The lot number of the prescription drug; and

15 (6) The name of the manufacturer of the finished dosage form.

16 (g) Each pedigree or electronic file shall be:

17 (1) Maintained by the purchaser and the wholesale distributor
 18 for three (3) years from the date of sale or transfer; and

19 (2) Available for inspection or use upon a request of an
 20 officer of the law.

21 (h) The board shall adopt rules and a form relating to the
 22 requirements of this section no later than ninety (90) days after the
 23 effective date of this subchapter.

24
 25 17-92-1205. Enforcement – Order to cease distribution of a drug.

26 (a) The Arkansas State Board of Pharmacy shall issue an order
 27 requiring the appropriate person including the manufacturers, distributors,
 28 or retailers of the drug to immediately cease distribution of the drug if the
 29 Arkansas State Board of Pharmacy finds that there is a reasonable probability
 30 that:

31 (1) A wholesale distributor has:

32 (A) Violated a provision in this subchapter; or

33 (B) Falsified a pedigree or sold, distributed,
 34 transferred, manufactured, repackaged, handled, or held a counterfeit
 35 prescription drug intended for human use;

36 (2) The prescription drug at issue in subdivision (a)(1) of this

1 section could cause serious adverse health consequences or death; and

2 (3) Other procedures would result in unreasonable delay.

3 (b)(1) An order under subsection (a) of this section shall provide the
 4 person subject to the order with an opportunity for an informal hearing on
 5 the actions required by the order to be held not later than ten (10) days
 6 after the date of the issuance of the order.

7 (2) If after providing an opportunity for a hearing the board
 8 determines that inadequate grounds exist to support the actions required by
 9 the order, the board shall vacate the order.

10
 11 17-92-1206. Prohibited acts.

12 It is unlawful for a person to perform or cause the performance of or
 13 aid and abet any of the following acts in this state:

14 (1) Failing to obtain a license in accordance with this
 15 subchapter;

16 (2) Operating without a valid license if a license is required
 17 by this subchapter;

18 (3) Purchasing or otherwise receiving a prescription drug from a
 19 pharmacy unless the requirements in § 17-92-1203 are met;

20 (4) Selling, distributing, or transferring a prescription drug
 21 to a person who is not authorized under the laws of the state in which the
 22 person receives the prescription drug in violation of § 17-92-1203;

23 (5) Failing to deliver prescription drugs to specified premises
 24 as required by § 17-92-1203;

25 (6) Accepting payment or credit for the sale of prescription
 26 drugs in violation of § 17-92-1203;

27 (7) Failing to maintain or provide pedigrees as required by this
 28 subchapter;

29 (8) Failing to obtain, pass, or authenticate a pedigree as
 30 required by this subchapter;

31 (9) Providing the state or any of its representatives or any
 32 federal official with false or fraudulent records or making false or
 33 fraudulent statements regarding any matter within the provisions of this
 34 subchapter;

35 (10) Obtaining or attempting to obtain a prescription drug by
 36 fraud, deceit, or misrepresentation or engaging in misrepresentation or fraud

1 in the distribution of a prescription drug;

2 (11) Manufacturing, repacking, selling, transferring,
3 delivering, holding, or offering for sale any prescription drug that is
4 adulterated, misbranded, counterfeit, suspected of being counterfeit, or has
5 otherwise been rendered unfit for distribution;

6 (12) Adulterating, misbranding, or counterfeiting any
7 prescription drug;

8 (13) Receiving any prescription drug that is adulterated,
9 misbranded, stolen, obtained by fraud or deceit, counterfeit, or suspected of
10 being counterfeit coupled with delivering or proffering delivery of the drug
11 for pay or otherwise; and

12 (14) Altering, mutilating, destroying, obliterating, or removing
13 the whole or any part of the labeling of a prescription drug or the
14 commission of any other act with respect to a prescription drug that results
15 in the prescription drug's being misbranded.

16
17 17-92-1207. Penalties.

18 (a) If a person engages in the wholesale distribution of prescription
19 drugs in violation of this subchapter, the person shall be imprisoned for not
20 more than fifteen (15) years or fined not more than fifty thousand dollars
21 (\$50,000), or both.

22 (b) If a person knowingly engages in wholesale distribution of
23 prescription drugs in violation of this subchapter, the person shall be
24 imprisoned for any term of years or fined not more than five hundred thousand
25 dollars (\$500,000), or both.